Epileptogenesis

Epileptogenesis is the gradual process by which a normal brain develops epilepsy. Epilepsy is a chronic condition in which seizures occur.[1] These changes to the brain occasionally cause neurons to fire in an abnormal, hypersynchronous manner, known as a seizure.[2]

Causes

The causes of epilepsy are broadly classified as genetic, structural/metabolic, or unknown.[3] Anything that causes epilepsy causes epileptogenesis, because epileptogenesis is the process of developing epilepsy. Structural causes of epilepsy include neurodegenerative diseases, traumatic brain injury, stroke, brain tumor, infections of the central nervous system, and status epilepticus (a prolonged seizure or a series of seizures occurring in quick succession).[4]

Latent period

After a brain injury occurs, there is frequently a "silent" or "latent period" lasting months or years in which seizures do not occur;[5] Canadian neurosurgeon Wilder Penfield called this time between injury and seizure "a silent period of strange ripening".[6] During this latent period, changes in the physiology of the brain result in the development of epilepsy.[5] This process, during which hyperexcitable neural networks form, is referred to as epileptogenesis.[5] If researchers come to better understand epileptogenesis, the latent period may allow healthcare providers to interfere with the development of epilepsy or to reduce its severity.[5]

Pathophysiology

Changes that occur during epileptogenesis are poorly understood but are thought to include cell death, axonal sprouting, reorganization of neural networks, alterations in the release of neurotransmitters, and neurogenesis.[4] These changes cause neurons to become hyperexcitable and can lead to spontaneous seizures.[4]

Brain regions that are highly sensitive to insults and can cause epileptogenesis include temporal lobe structures such as the hippocampus, the amygdala, and the piriform cortex.[5]

Neural reorganization

In addition to chemical processes, the physical structure of neurons in the brain may be altered. In acquired epilepsy in both humans and animal models, pyramidal neurons are lost, and new synapses are formed.[2]

Hyperexcitability, a characteristic feature of epileptogenesis in which the likelihood that neural networks will be activated is increased, may be due to loss of inhibitory neurons, such as GABAergic interneurons, that would normally balance out the excitability of other neurons.[2] Neuronal circuits that are epileptic are known for being hyperexcitable and for lacking the normal balance of glutamatergic neurons (those that usually increase excitation) and GABAergic ones (those that decrease it).[5] In addition, the levels of GABA and the sensitivity of GABAA receptors to the neurotransmitter may decrease, resulting in less inhibition.[2]

Another proposed mechanism for epileptogenesis in TBI is that damage to white matter causes hyperexcitability by effectively undercutting the cerebral cortex.[7]

Glutamate receptor activation

It is believed that activation of biochemical receptors on the surfaces of neurons is involved in epileptogenesis; these include the TrkB neurotrophin receptor and both ionotropic glutamate receptors and metabotropic glutamate receptors (those that are directly linked to an ion channel and those that are not, respectively).[1] Each of these types of receptor may, when activated, cause an increase in the concentration of calcium ions (Ca2+) within the area of the cell on which the receptors are located, and this Ca2+ can activate enzymes such as Src and Fyn that may lead to epileptogenesis.[1]

Excessive release of the neurotransmitter glutamate is widely recognized as an important part of epileptogenesis early after a brain injury, including in humans.[5] Excessive release of glutamate results in excitotoxicity, in which neurons are excessively depolarized, intracellular Ca2+ concentrations increase sharply, and cellular damage or death results.[5] Excessive glutamatergic activity is also a feature of neuronal circuits after epilepsy has developed, but glutamate does not appear to play an important role in epileptogenesis during the latent period.[5] Another factor in hyperexcitability may include a decrease in the concentration of Ca2+ outside cells (i.e. in the extracellular space) and a decrease in the activity of ATPase in glial cells.[2]

Blood brain barrier disruption

Blood brain barrier (BBB) disruption occurs in high prevalence following all brain lesions that may cause post injury epilepsy such as stroke, traumatic brain injury, brain infection or brain tumor.[8] BBB disruption was shown to underlay epileptogenesis by several experimental models.[9][10] Furthermore, it was shown that albumin, the most frequent protein in the serum is the agent that leaks from the blood into the brain parenchyma under BBB disruption conditions and induces epileptogenesis by activation of the transforming growth factor beta receptor on astrocytes.[11][12][13] Additional investigation exposed that this process is mediated by a unique inflammatory pattern [12][14] and the formation of excitatory synapses.[15] Pathogenic influence was attributed also to the extravasation of other blood born substances such as hemosiderin or iron.[7] Iron from hemoglobin, a molecule in red blood cells, can lead to the formation of free radicals that damage cell membranes; this process has been linked to epileptogenesis.[16]

Treatment

A major goal of epilepsy research is the identification of therapies to interrupt or reverse epileptogenesis. Studies largely in animal models have suggested a wide variety of possible antiepileptogenic strategies although, to date, no such therapy has been demonstrated to be antiepileptogenic in clinical trials.[17] Some anticonvulsant drugs, including levetiracetam and ethosuximide have shown promising activity in animal models. Other promising strategies are inhibition of interleukin 1β signaling by drugs such as VX-765; modulation of sphingosine 1-phosphate signaling by drugs such as fingolimod; activation of the mammalian target of rapamycin (mTOR) by drugs such as rapamycin; the hormone erythropoietin; and, paradoxically, drugs such as the α2 adrenergic receptor antagonist atipamezole and the CB1 cannabinoid antagonist SR141716A (rimonabant) with proexcitatory activity. The discovery of the role played by TGF-beta activation in epileptogenesis raised the hypothesis that blocking this signaling may prevent epileptogenesis. Losartan, a commonly used drug for the treatment of hypertension was shown to prevent epilepsy and facilitate BBB healing in animal models. Testing the potential of antiepileptogenic agents (e.g losartan) or BBB healing drugs necessitates biomarkers for patients selection and treatment-followup.[18] BBB disruption imaging was shown capacity in animal model to serve as a biomarker of epileptogenesis [19] and specific EEG patterns were also shown to predict epilepsy in several models.[20]

History

Throughout most of history for which written records exist on the subject, it was probably generally believed that epilepsy came about through a supernatural process.[21] Even within the medical profession, it was not until the 18th century that ideas of epileptogenesis as a supernatural phenomenon were abandoned.[21] However, biological explanations have also long existed, and sometimes explanations contained both biological and supernatural elements.[21]

Research

Epileptogenesis that occurs in human brains has been modeled in a variety of animal models and cell culture models.[1] Epileptogenesis is poorly understood,[5] and increasing understanding of the process may aid researchers in preventing seizures, diagnosing epilepsy,[22] and developing treatments to prevent it.[1]

See also

References

  1. 1 2 3 4 5 McNamara JO, Huang YZ, Leonard AS (October 2006). "Molecular signaling mechanisms underlying epileptogenesis". Sci. STKE. 2006 (356): re12. doi:10.1126/stke.3562006re12. PMID 17033045.
  2. 1 2 3 4 5 Armijo JA, Valdizán EM, De Las Cuevas I, Cuadrado A (2002). "Advances in the physiopathology of epileptogenesis: Molecular aspects". Rev Neurol (in Spanish). 34 (5): 409–29. PMID 12040510.
  3. ↑ Noebels, Jeffrey L.; Avoli, Massimo (2012-06-29). Jasper's Basic Mechanisms of the Epilepsies. Oxford University Press. p. 3. ISBN 9780199746545. Retrieved 2014-10-16.
  4. 1 2 3 Herman ST (January 2006). "Clinical trials for prevention of epileptogenesis". Epilepsy Res. 68 (1): 35–8. doi:10.1016/j.eplepsyres.2005.09.015. PMID 16377141.
  5. 1 2 3 4 5 6 7 8 9 10 Aroniadou-Anderjaska V, Fritsch B, Qashu F, Braga MF (February 2008). "Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy". Epilepsy Res. 78 (2–3): 102–16. doi:10.1016/j.eplepsyres.2007.11.011. PMC 2272535. PMID 18226499.
  6. ↑ "Post-traumatic epilepsy". Br Med J. 2 (6132): 229. 1978. doi:10.1136/bmj.2.6132.229. PMC 1606365. PMID 98198.
  7. 1 2 Firlik KS, Spencer DD (2004). "Surgery of post-traumatic epilepsy". In Dodson WE, Avanzini G, Shorvon SD, Fish DR, Perucca E (eds.). The Treatment of Epilepsy. Oxford: Blackwell Science. p. 775. ISBN 0-632-06046-8. Retrieved 2008-06-09.
  8. ↑ Schevon CA, Tobochnik S, Eissa T, Merricks E, Gill B, Parrish RR, Bateman LM, McKhann GM Jr, Emerson RG, Trevelyan AJ (2019). "Multiscale recordings reveal the dynamic spatial structure of human seizures". Neurobiol Dis. 127: 303–311. doi:10.1016/j.nbd.2019.03.015. PMC 6588430. PMID 30898669.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ↑ Seiffert E, Dreier JP, Ivens S, Bechmann I, Heinemann U, Friedman A (2004). "Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J". Neuroscience. 24 (36): 7829–36. doi:10.1523/JNEUROSCI.1751-04.2004. PMID 15356194.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ↑ van Vliet EA, da Costa Araujo S, Redeker S, van Schaik R, Aronica E, Gorter JA (2007). "Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy". Brain. 130 (2): 521–534. doi:10.1093/brain/awl318. PMID 17124188.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ↑ Ivens S, Kaufer D, Seiffert E, Bechmann I, Tomkins O, Heinemann U, Friedman A (2007). "TGF-beta receptor mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis". Brain. 130 (Pt 2): 535–47. doi:10.1093/brain/awl317. PMID 17121744.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. 1 2 Cacheaux LP, Ivens S, David Y, Lakhter AJ, Bar-Klein G, Shapira M, Heinemann U, Friedman A, Kaufer D (2009). "Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis". Journal of Neuroscience. 29 (28): 8927–8935. doi:10.1523/JNEUROSCI.0430-09.2009. PMC 2875073. PMID 19605630.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ↑ David Y, Flores LP, Ivens S, Heinemann U, Kaufer D, Friedman A (2009). "Astrocytic dysfunction in epileptogenesis: consequences of altered potassium and glutamate buffering?". Journal of Neuroscience. 29 (34): 10588–99. doi:10.1523/JNEUROSCI.2323-09.2009. PMC 2875068. PMID 19710312.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ↑ Levy N, Milikovsky DZ, Baranauskas G, Vinogradov E, David Y, Ketzef M, Abutbul S, Weissberg I, Kamintsky L, Fleidervish I, Friedman A, Monsonego A (2015). "Differential TGF-β Signaling in Glial Subsets Underlies IL-6-Mediated Epileptogenesis in Mice". J Immunol. 195: 1713–22. doi:10.4049/jimmunol.1401446. PMID 26136430.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  15. ↑ Weissberg I, Wood L, Kamintsky L, Vazquez O, Milikovsky DZ, Alexander A, Oppenheim H, Ardizzone C, Becker A, Frigerio F, Vezzani A, Buckwalter MS, Huguenard JR, Friedman A, Kaufer D (2015). "Albumin induces excitatory synaptogenesis through astrocytic TGF-β/ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunction". Neurobiol Dis. 78: 115–25. doi:10.1016/j.nbd.2015.02.029. PMC 4426044. PMID 25836421.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. ↑ Beghi E (2004). "Aetiology of epilepsy". In Dodson WE, Avanzini G, Shorvon SD, Fish DR, Perucca E (eds.). The Treatment of Epilepsy. Oxford: Blackwell Science. p. 61. ISBN 0-632-06046-8. Retrieved 2008-06-09.
  17. ↑ Kaminski, R. M.; Rogawski, M. A.; Klitgaard, H (2014). "The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments". Neurotherapeutics. 11 (2): 385–400. doi:10.1007/s13311-014-0266-1. PMC 3996125. PMID 24671870.
  18. ↑ Friedman A, Bar-Klein G, Serlin Y, Parmet Y, Heinemann U, Kaufer D (2014). "Should losartan be administered following brain injury?". Expert Rev Neurother. 14: 1365–75. doi:10.1586/14737175.2014.972945. PMID 25346269.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  19. ↑ Bar-Klein G, Lublinsky S, Kamintsky L, Noyman I, Veksler R, Dalipaj H, Senatorov VV Jr, Swissa E, Rosenbach D, Elazary N, Milikovsky DZ, Milk N, Kassirer M, Rosman Y, Serlin Y, Eisenkraft A, Chassidim Y, Parmet Y, Kaufer D, Friedman A (2017). "Imaging blood-brain barrier dysfunction as a biomarker for epileptogenesis". Brain. 140: 1692–1705. doi:10.1093/brain/awx073. PMID 28444141.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  20. ↑ Milikovsky DZ, Weissberg I, Kamintsky L, Lippmann K, Schefenbauer O, Frigerio F, Rizzi M, Sheintuch L, Zelig D, Ofer J, Vezzani A, Friedman A (2017). "Electrocorticographic Dynamics as a Novel Biomarker in Five Models of Epileptogenesis". J Neurosci. 37: 4450–4461. doi:10.1523/JNEUROSCI.2446-16.2017. PMC 6596657. PMID 28330876.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  21. 1 2 3 Eadie MJ, Bladin PF (2001). "The interpretation of the epileptic process". A Disease Once Sacred: A History of the Medical Understanding of Epilepsy. London: John Libbey. p. 80. ISBN 0-86196-607-4. Retrieved 2008-06-12.
  22. ↑ Leśkiewicz M, Lasoń W (2007). "The neurochemical mechanisms of temporal lobe epilepsy: an update". Prz. Lek. (in Polish). 64 (11): 960–4. PMID 18409413.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.